Skip to main content
logo
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
54.65
+9.47 (20.96%)
At close: Mar 6, 2026

HKG:2315 Revenue

In the year 2025, Biocytogen Pharmaceuticals (Beijing) had annual revenue of 1.38B CNY with 40.63% growth. Biocytogen Pharmaceuticals (Beijing) had revenue of 620.96M in the half year ending June 30, 2025, with 89.99% growth.

Revenue
1.38B CNY
Revenue Growth
+40.63%
P/S Ratio
23.20
Revenue / Employee
1.06M CNY
Employees
1,306
Market Cap
35.60B HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20251.38B398.35M40.63%
Dec 31, 2024980.45M263.54M36.76%
Dec 31, 2023716.91M183.03M34.28%
Dec 31, 2022533.88M179.33M50.58%
Dec 31, 2021354.56M101.01M39.84%
Dec 31, 2020 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
3SBio9.94B
Genscript Biotech6.50B
Shanghai Henlius Biotech6.35B
RemeGen3.62B
Zai Lab3.58B
Shanghai Junshi Biosciences2.78B
Duality Biotherapeutics2.38B
InnoCare Pharma1.56B
Revenue Rankings

Biocytogen Pharmaceuticals (Beijing) News

More News